Gert Lennart Perlhagen

Biography

Lennart Perlhagen was a founding investor in Novocure, has been a director of the Company since its inception in 2003 and has served on our compensation committee since 2012. Mr. Perlhagen is an active entrepreneur and investor in emerging healthcare companies. He founded Meda AB as part of its merger with Cross Pharma AB and, from 1999 to 2006, served as a director on its board.  Meda AB is a leading specialty Swedish pharmaceutical company that grew from a market capitalization of USD $10 million to over $4.0 billion during his tenure with the company.  Prior to founding Meda AB, Mr. Perlhagen was the Chief Executive Officer for Scandinavia and the UK for Farmitalia SpA (later acquired by Pfizer), where he gained extensive experience in oncology through the launch of the chemotherapy agent Adriamycin (doxorubicin).  Additionally, Mr. Perlhagen helped lead the commercial launch of Losec/Prilosec (omeprazole) for Astra AB, a specialty pharmaceutical company now known as Astra-Zeneca, where he served as Regional Director for South Europe and as a member of the International Marketing Strategy Group.

Research Interest

Marketing